464 related articles for article (PubMed ID: 11412836)
1. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
2. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
Parada A; Soares-da-Silva P
Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Soares-da-Silva P; Vieira-Coelho MA; Parada A
Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
7. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
8. Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
Okada M; Nakao R; Hosoi R; Zhang MR; Fukumura T; Suzuki K; Inoue O
J Cereb Blood Flow Metab; 2011 Jan; 31(1):124-31. PubMed ID: 20407462
[TBL] [Abstract][Full Text] [Related]
9. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
[TBL] [Abstract][Full Text] [Related]
11. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Kaakkola S; Wurtman RJ
J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
[TBL] [Abstract][Full Text] [Related]
12. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.
Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P
Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
Nissinen E; Lindén IB; Schultz E; Pohto P
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
[TBL] [Abstract][Full Text] [Related]
14. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
[TBL] [Abstract][Full Text] [Related]
15. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.
Kent AP; Stern GM; Webster RA
Br J Pharmacol; 1990 Aug; 100(4):743-8. PubMed ID: 2119841
[TBL] [Abstract][Full Text] [Related]
16. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
17. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
Männistö PT; Tuomainen P; Toivonen M; Törnwall M; Kaakkola S
J Neural Transm Park Dis Dement Sect; 1990; 2(1):31-43. PubMed ID: 2113389
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
[TBL] [Abstract][Full Text] [Related]
19. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
20. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.
Waldmeier PC; De Herdt P; Maitre L
J Neural Transm Suppl; 1990; 32():381-6. PubMed ID: 2128510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
